Insider Selling: Theravance Biopharma (NASDAQ:TBPH) SVP Sells $433,695.32 in Stock

Theravance Biopharma, Inc. (NASDAQ:TBPH) SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Theravance Biopharma Trading Up 2.3%

Shares of TBPH stock opened at $14.33 on Friday. Theravance Biopharma, Inc. has a 12-month low of $7.90 and a 12-month high of $21.03. The business’s fifty day simple moving average is $18.00 and its 200-day simple moving average is $16.85. The company has a market cap of $726.10 million, a PE ratio of 7.06 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings data on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.71. Theravance Biopharma had a return on equity of 18.55% and a net margin of 98.54%.The firm had revenue of $45.89 million during the quarter, compared to analysts’ expectations of $43.09 million. On average, equities analysts forecast that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Trending Headlines about Theravance Biopharma

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

Institutional Trading of Theravance Biopharma

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. grew its holdings in Theravance Biopharma by 2.5% during the third quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company’s stock worth $32,289,000 after acquiring an additional 54,152 shares during the period. State Street Corp raised its position in Theravance Biopharma by 4.4% during the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company’s stock valued at $20,616,000 after acquiring an additional 45,987 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Theravance Biopharma by 4.5% in the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company’s stock valued at $17,567,000 after acquiring an additional 40,734 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Theravance Biopharma by 12.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company’s stock valued at $16,072,000 after acquiring an additional 92,253 shares during the period. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in Theravance Biopharma in the 3rd quarter worth approximately $10,611,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on TBPH. B. Riley Financial restated a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research note on Wednesday, March 4th. HC Wainwright lifted their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Wall Street Zen downgraded shares of Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Saturday. BTIG Research restated a “buy” rating and set a $21.00 price target on shares of Theravance Biopharma in a research note on Friday. Finally, Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.60.

About Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.